Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer

doi:10.4251/wjgo.v18.i2.115515

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 2

This Article

(45)

(29)

(0)

(1051)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Oncol. Feb 15, 2026; 18(2): 115515
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115515

Full Size Figure Download Figure

Figure 4 Forest plots for the meta-analysis of the association between liver metastasis and overall survival in patients with metastatic colorectal cancer treated with immune checkpoint inhibitors. A: Overall meta-analysis; B: Subgroup analysis according to study design; C: Subgroup analysis according to the type of metastatic colorectal cancer. 95%CI: 95% confidence interval.

Citation: Xiang MY, Tuo ZM, Sa XK, Wang P, Bian JW, Zhang XM. Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer. World J Gastrointest Oncol 2026; 18(2): 115515
URL: https://www.wjgnet.com/1948-5204/full/v18/i2/115515.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i2.115515

Xiang MY, Tuo ZM, Sa XK, Wang P, Bian JW, Zhang XM. Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer. World J Gastrointest Oncol 2026; 18(2): 115515 [PMID: 41695937 DOI: 10.4251/wjgo.v18.i2.115515]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.